Avalo Therapeutics Inc. (NASDAQ: AVTX)
$6.2100
-0.3100 ( -4.90% ) 52.1K
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Market Data
Open
$6.2100
Previous close
$6.5200
Volume
52.1K
Market cap
$65.71M
Day range
$6.2350 - $6.9000
52 week range
$3.9501 - $34.4600
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 3 | Insider transactions | 2 | Jan 03, 2025 |
| 4 | Insider transactions | 1 | Jan 03, 2025 |
| 8-k | 8K-related | 16 | Jan 02, 2025 |
| 8-k | 8K-related | 38 | Dec 05, 2024 |
| 4 | Insider transactions | 1 | Nov 14, 2024 |
| 8-k | 8K-related | 42 | Nov 12, 2024 |
| 10-q | Quarterly Reports | 73 | Nov 07, 2024 |
| 8-k | 8K-related | 15 | Nov 07, 2024 |
| 8-k | 8K-related | 42 | Oct 08, 2024 |
| 8-k | 8K-related | 37 | Sep 09, 2024 |